ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 256 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $281,000 | +1.1% | 7,981 | +32.0% | 0.01% | -9.1% |
| Q1 2022 | $278,000 | -29.8% | 6,045 | +1.2% | 0.01% | -31.2% |
| Q4 2021 | $396,000 | +6.7% | 5,973 | +0.5% | 0.02% | -5.9% |
| Q3 2021 | $371,000 | -34.3% | 5,943 | -12.9% | 0.02% | -34.6% |
| Q2 2021 | $565,000 | +29.6% | 6,822 | +3.8% | 0.03% | +13.0% |
| Q1 2021 | $436,000 | -21.9% | 6,575 | -9.6% | 0.02% | -42.5% |
| Q4 2020 | $558,000 | +58.5% | 7,272 | -11.0% | 0.04% | +29.0% |
| Q3 2020 | $352,000 | -37.0% | 8,175 | -36.8% | 0.03% | -41.5% |
| Q2 2020 | $559,000 | +50.7% | 12,943 | +0.4% | 0.05% | +35.9% |
| Q1 2020 | $371,000 | -54.6% | 12,895 | -0.0% | 0.04% | -43.5% |
| Q4 2019 | $818,000 | +108.7% | 12,896 | -7.3% | 0.07% | +86.5% |
| Q3 2019 | $392,000 | +6.5% | 13,911 | +0.2% | 0.04% | +2.8% |
| Q2 2019 | $368,000 | – | 13,887 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |